Go back to Resources

Sirolimus Is Associated With Veno-Occlusive Disease of the Liver After Myeloablative Allogeneic Stem Cell Transplantation

Dec-08

Journal Article

Authors:

Cutler, C.

Stevenson, K.

Kim, H.T.

Richardson, P.

Ho, V.T.

Linden, E.

Revta, C.

Ebert, R.

Warren, D.

Choi, S.

Koreth, J.

Armand, P.

Alyea, E.

Carter, S.

Horowitz, M.

Antin, J.H.

Soiffer, R.

Secondary:
Blood

Volume:
112

Pagination:
4425-4431

URL:
http://www.ncbi.nlm.nih.gov/pubmed/18776081

Keywords:
Drug Combinations; Female; Graft vs Host Disease/prevention & control; Hematopoietic Stem Cell Transplantation*/methods; Hepatic Veno-Occlusive Disease/chemically induced*; Hepatic Veno-Occlusive Disease/epidemiology; Humans; Immunosuppressive Agents

Abstract:
<p>{Sirolimus is an effective agent used in graft-versus-host disease (GVHD) prophylaxis after allogeneic transplantation. It also has antiproliferative effects on vascular endothelium when used to coat coronary artery stents. We noted an excess of veno-occlusive disease (VOD) in a clinical trial, and retrospectively reviewed the records of 488 patients to determine the association between sirolimus and VOD. When used with cyclophosphamide/total body irradiation (Cy/TBI) conditioning, sirolimus is associated with an increased incidence of VOD (OR 2.35</p>

Go back to Resources